Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

CONCLUSIONS The nonspecific, long-acting sulfonylureas glyburide and glimepiride do not have an increased risk of cardiovascular adverse events compared with the specific, short-acting sulfonylureas gliclazide, glipizide, and tolbutamide. However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia.

http://care.diabetesjournals.org/cgi/content/short/40/11/1506?rss=1

Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Douros, A.; Yin, H.; Yu, O. H. Y.; Filion, K. B.; Azoulay, L.; Suissa, S. Tags: Epidemiology-Cardiovascular Disease Epidemiology/Health Services Research Source Type: research